ERBB2 and gastric cancer: Unlike targeted therapy where the mechanism of action may be dependent upon a more limited set of molecular aberrations, such as HER2 overexpression and response to trastuzumab in breast and gastric cancers, cytotoxic effects from Pt agents are dependent upon a host of factors, including intravenous delivery of the agent to the tumor and the cellular response to DNA damage [22].